Preliminary data from the ADVANCE Phase 1/2 Study in A1AT deficiency showed ADVM-043 in ...
Strategic Licensing Collaboration with Janssen Expanded TRACON’s Oncology Portfolio and Validated Company’s Unique Clinical ...
RANCHO CORDOVA, Calif., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL) ...
